Introduction
============

According to the International Association for the Study of Pain, neuropathic pain (NeP) is characterized by a "pain arising as a direct consequence of a lesion or disease of the somatosensory system".[@b1-jpr-10-2525] However, identification of NeP is challenging, given its association with other pain processes and the absence of a "gold standard" diagnostic test. Not surprisingly, it can be difficult to treat effectively and is associated with significant impairments in health-related quality of life along with a substantial economic burden.[@b2-jpr-10-2525],[@b3-jpr-10-2525]

The existing literature has primarily investigated the epidemiology of NeP within the context of specific diseases, such as cancer, diabetic peripheral neuropathy (DPN), and chronic low-back pain (CLBP). For example, systematic reviews of patients with cancer have reported prevalence rates of NeP at 19%,[@b4-jpr-10-2525] with similar estimates (20%) among patients with type 2 diabetes.[@b5-jpr-10-2525]--[@b9-jpr-10-2525] However, as obesity rates and associated comorbid conditions, such as diabetes and CLBP (resulting from lumbar surgery interventions), continue to increase in the US, the total number of people experiencing NeP is likely to continue to grow.[@b10-jpr-10-2525]--[@b13-jpr-10-2525] These trends highlight the need to examine the prevalence of NeP broadly, rather than from a disease-specific perspective.

In spite of the challenges associated with defining NeP, estimating the population prevalence is critical for a number of reasons, including but not limited to quantifying the potential societal burden, calculating the potential health care needs of this population, and guiding health policies. This is particularly pertinent, given that the majority of patients with NeP are treated by primary care physicians in the community, who do not necessarily specialize in the diagnosis or management of NeP.[@b14-jpr-10-2525]

To date, the largest NeP-prevalence study conducted in the US, using data from a survey, phone, and clinical examinations, found a prevalence rate of 9.8% among adult Minnesotans.[@b15-jpr-10-2525] The current exploratory study estimates the prevalence of NeP, both overall and among those with pain, using data collected from a nationwide survey.

Materials and methods
=====================

Sampling
--------

Data for this study were collected using a cross-sectional survey of adults in the US (aged 18 years and older). The sample size was calculated to ensure a level of precision in each sex-by-age-by ethnicity stratum (the smallest anticipated unit for prevalence calculations) that would not exceed ±2.5%. Subsequently, there is a 95% probability that the true population prevalence resides within 2.5% of the reported-prevalence estimate from our sample. This sample size was larger than what would be required if the true prevalence was around 20%. Participants were recruited via Internet, mail, telephone, shopping-mall interception, and retail store-receipt solicitation. This multimodal approach was used to maximize external validity and avoid potential biases that could occur if only a single approach were used. The frequency of each method was selected to enhance study feasibility and minimize recruiting time (eg, fewer respondents were recruited via mailing lists, because it requires more time and effort to receive responses than other modalities, such as the Internet).

The sampling frame was designed to ensure adequate numbers of participants were included within each age, sex, and race/ethnicity stratum so that reasonable population-prevalence estimates could be derived. Older (65 years of age and above) and minority respondents were oversampled relative to their true proportions in the population to ensure that there were at least 100 participants in each cell (see [Table 1](#t1-jpr-10-2525){ref-type="table"}). Sampling weights were calculated to adjust the demographic characteristics of the sample to reflect the total adult US population.

Recruitment
-----------

Participants were recruited from August 2014 to October 2014. Members from several Internet panels (Lightspeed,[@b16-jpr-10-2525] Survey Sampling International,[@b17-jpr-10-2525] and Toluna[@b18-jpr-10-2525]) were recruited for this study using previously established methods for mail and Internet surveys[@b19-jpr-10-2525] and subgroup solicitation.[@b20-jpr-10-2525] Potential participants were organized into demographic strata (eg, non-Hispanic White males aged 18--34 years, non-Hispanic White males aged 35--44 years). Then, random sampling was used to identify potential participants within each stratum. Selected individuals were emailed an invitation to complete the survey. Those who clicked on the link were taken to a statement of informed consent, which described the study as a general health survey. Consenters completed an online questionnaire.

Mailing and calling lists (purchased from Marketing Systems Group)[@b21-jpr-10-2525] compiled from phone books and other sources were also used to recruit participants. These lists totaled over 153 million unique records. Potential respondents were first identified by age, sex, and race/ethnicity, and then either randomly mailed or called to ascertain interest. Those on the mailing list (n=80,004) were sent a paper version of the statement of informed consent, the survey, and a self-addressed stamped envelope so that they could return the materials to the research team. A total of 181,770 people on the telephone list were contacted by trained interviewers. Those who were willing to participate and who reported experiencing any pain in the previous 12 months were then asked whether they would prefer to complete the remainder of the survey using the Internet or receive materials by mail, since the PainDetect has not been validated for telephone administration.

To increase sample size, two additional recruitment methods were implemented during the last year of the study. In the first, trained researchers recruited a convenience sample of participants from 20 different shopping malls across the US. Those who were interested completed the informed consent and survey via computer. In the second modality, customers at pharmacies, grocery stores, and convenience stores were supplied with store receipts that included an invitation encouraging them to participate in the study. It directed them to a website that included the statement of informed consent and (upon completion) a link to the survey. All respondents were financially compensated between \$1 and \$10, depending on the recruitment modality. The study materials were reviewed and approved by an independent institutional review board (Sterling IRB, Atlanta, GA; protocol 161101387-2).

Data handling
-------------

For participants completing the survey via the Internet, data entry was completed instantaneously as the respondent answered the survey questions. For participants recruited via telephone, their data were entered manually into the online survey by the telephone interviewer. Respondents participating by mail had their responses manually entered into the database. All data were stored in a relational database, which housed the questionnaire responses and allowed for direct export into statistical software programs. With respect to analysis, all programming and outputs were reviewed by at least two independent researchers.

Measures
--------

All respondents provided their sex, age, race/ethnicity, state of residence, and whether they had experienced any of 19 health conditions or any pain within the last 12 months. Those who self-reported experiencing any pain within the last 12 months were asked to complete the PainDetect, a validated NeP-screening tool and other questions, including demographic, physical, and psychiatric comorbidities, pain types, and medication use.

The PainDetect is a screening tool used to assess the presence of NeP.[@b22-jpr-10-2525] Psychometric analyses indicate it can be used in a number of NeP subpopulations, including CLBP,[@b22-jpr-10-2525] peripheral nerve damage,[@b23-jpr-10-2525] HIV,[@b24-jpr-10-2525]--[@b26-jpr-10-2525] posttrauma/postsurgical injury,[@b24-jpr-10-2525]--[@b26-jpr-10-2525] spinal cord injury,[@b24-jpr-10-2525]--[@b26-jpr-10-2525] small-fiber neuropathy,[@b24-jpr-10-2525]--[@b26-jpr-10-2525] neck and shoulder pain,[@b23-jpr-10-2525] and osteoarthritis of the knee,[@b27-jpr-10-2525] as well as a heterogeneous NeP sample.[@b28-jpr-10-2525] The questionnaire does not perform as well in people with neck/upper-limb pain[@b29-jpr-10-2525] or fibromyalgia, who were not included in this study.[@b30-jpr-10-2525]

Like other NeP-screening measures, the PainDetect includes verbal descriptors and clinical characteristics. It is comprised of three components: pain intensity, pain-course pattern, and gradations of pain. For the first part, respondents used a 0--10 numerical rating scale to report their pain at the time they were completing the questionnaire. Two other items asked participants to use the same rating scale to report the strongest pain and average pain during the preceding 4 weeks. Then, four graphs were presented, and the respondent was asked to choose which best described the course of their pain. Each graph was accompanied by one of the following labels: "persistent pain with slight fluctuations", "persistent pain with pain attacks", "pain attacks without pain between them", or "pain attacks with pain between them". The third part asked respondents to rate the intensity of seven different pain sensations (eg, burning, tingling) on a scale from 0 (never) to 5 (very strongly).

A total PainDetect score for each respondent was generated by summing the number of points earned on each of the three sections. The screening tool has been shown to have over 80% sensitivity and specificity in paper-and-pencil form, and responses between that format and electronic administration of the instrument were found to be equivalent.[@b31-jpr-10-2525] PainDetect scores can be categorized into three groups: unlikely NeP (0--12), "unlikely" (13--18), and positive/likely NeP (≥19).[@b22-jpr-10-2525] Since this study focused on estimating the prevalence of NeP, scores were dichotomized into "unlikely NeP" (0--18) and "probable NeP" (≥19), which indicates the patient is at risk of NeP.

Participants reported whether they experienced any physical pain in the last 12 months. Those that answered yes completed the PainDetect. Then, participants reported their pain-related experiences. Next, using a checklist, they selected pains that they had experienced for at least 3 of the last 12 months. Then, participants were asked: "Is the pain that you are experiencing nerve pain?" To ensure comprehension, participants were told: "Nerve pain may be described as the feeling of being pricked with pins and needles, shocked by electricity, or may include numbness, burning, or tingling, and can be due to irritation or damage to the nerve. For example, nerve pain from diabetes is often experienced as burning or tingling, and can be due to irritation or damage to the nerve."

They were then supplied with a checklist that included the same pain types and asked to indicate yes or no for each. Additionally, participants also reported the duration of each pain type by indicating whether it was less than 1 year, between 1 and 5 years, or longer than 5 years. Finally, participants were asked to report the medications they were taking if they experienced nerve pain for at least 3 of the last 12 months. For this item, participants were provided a comprehensive list of medications specified by their trade and generic names and space to report medications not on the list. The medications were then categorized into 13 classes using the Institute of Medicine's taxonomy[@b32-jpr-10-2525] ([Table S1](#SD1-jpr-10-2525){ref-type="supplementary-material"}).

Statistical analyses
--------------------

The study was designed to estimate the prevalence of probable NeP by demographic strata. To achieve this objective, older (65 years and above) and minority respondents were oversampled. Sampling weights were calculated to adjust the proportions of demographic strata so that the rate aligned with the June 2015 Current Population Survey of the US Census.[@b33-jpr-10-2525]

Frequencies for the sample and the US population were calculated for sociodemographic variables, questionnaire modality, and region of residence. This was followed by calculation of the PainDetect scores and categorization of respondents into probable NeP and unlikely NeP groups. Then, weighted generalized linear models specifying a binomial distribution and controlling for age, sex, and race/ethnicity were used to estimate the adjusted mean percentages of those experiencing NeP by different questionnaire modality. A heat map was used to demonstrate the prevalence of probable NeP across sex, race, and age. Population estimates were used to report the proportions of the population with probable NeP and unlikely NeP by sex, age, race/ethnicity, and region of residence. Then, population estimates for comorbidity (physical and psychiatric) and pain type were derived for those with probable NeP and unlikely NeP. Next, means for the strongest and average pain items from the PainDetect were compared for those with probable and unlikely NeP and who had reported nerve pain for at least 3 of the last 12 months. Then, the frequency and percentage for duration of each pain type was calculated. Finally, population estimates of medication use were reported for those who reported NeP pain and those with likely NeP and self-reported NeP pain using the Institute of Medicine's taxonomy.[@b32-jpr-10-2525]

Corresponding 95% confidence intervals (CIs) are reported when appropriate. The majority of data were collected via Internet questionnaire, which did not allow for skipping items; therefore, analyses were performed on those with completed questionnaires. All analyses were conducted using SAS 9.3.

Results
=======

Prevalence of probable NeP
--------------------------

A total of 24,925 respondents were recruited using all five recruitment methods: Internet 15,088 (response rate 2.9%), mail 982 (response rate 1.2%), telephone 2,907 (response rate 1.6%), mall intercept 5,338, and store receipt 590 (response rate 0.3%). The average response rate was 2.5%. Over half (52.2%) of the respondents were female, and the mean age was 51.5 years (see [Table 1](#t1-jpr-10-2525){ref-type="table"}). Almost two-thirds (63.7%) of respondents reported they had experienced some form of physical pain in the past 12 months and completed the PainDetect to assess the presence of probable NeP (see [Figure 1](#f1-jpr-10-2525){ref-type="fig"}). The distribution of PainDetect scores is shown in [Figure 2](#f2-jpr-10-2525){ref-type="fig"} (mean 10.2, median 8). Among those who reported at least some pain in the past 12 months, a weighted estimate of 15.7% (95% CI 14.9%--16.5%) had probable NeP. This corresponded to a weighted probable NeP-prevalence estimate of 10% (95% CI 9.5%--10.5%) among all respondents.

The recruitment methods produced generally consistent prevalence estimates for probable NeP among adults experiencing pain (11.3%--17.2%). The calculated rate in the overall population was substantially more variable, and ranged from 4.1% to 12.4% (see [Table 2](#t2-jpr-10-2525){ref-type="table"}). There was substantial variation across demographic strata, as demonstrated in the heat map in [Figure 3](#f3-jpr-10-2525){ref-type="fig"}. Among adults experiencing any pain, probable NeP was most frequent among Hispanic males 35--44 years old (32.4%), Hispanic males 45--54 years old (24.2%), and non-Hispanic Black females 45--54 years old (24.1%).

Patient characteristics associated with probable NeP versus unlikely NeP
------------------------------------------------------------------------

The demographic composition of the probable and unlikely NeP groups were similar across sex; however, the probable-NeP group tended to be younger. The probable-NeP group included more minority participants in general and a much larger percentage of Hispanics. Most participants were from the South, but the probable-NeP group had fewer participants from the Midwest (see [Table 3](#t3-jpr-10-2525){ref-type="table"}). Respondents with probable NeP reported higher rates of psychiatric-related comorbidities compared with those unlikely to have NeP, such as anxiety (38% vs 25.1%), depression (34.5% vs 21.1%), insomnia (34.2% vs 24.7%), and pain-related conditions like fibromyalgia (10.1% vs 2.6%) and rheumatoid arthritis (14.5% vs 3.9%; see [Figure 4](#f4-jpr-10-2525){ref-type="fig"}).

Additionally, respondents with probable NeP reported higher rates of all pain types (see [Figure 5](#f5-jpr-10-2525){ref-type="fig"}). For example, those with probable NeP reported higher rates of arthritis/joint pain (48%), back pain (BP) (69.9%), and dental/facial pain (21.3%) compared to those with unlikely NeP, who reported rates of 35.4%, 52.9% and 13%, respectively, for the same conditions. Some of the largest differences were observed for diabetes-related pain (47.9% vs 20% among those with diabetes), spinal cord-injury pain (8.9% vs 1.5%), shingles-related pain (4.6% vs 0.9%), and surgical pain (12.5% vs 5.6%).

Self-reported nerve pain and medication use
-------------------------------------------

Those who reported nerve pain for at least 3 of the last 12 months and probable NeP (n=2,177) had higher scores on PainDetect items assessing the strongest pain (mean 8.35, 95% CI 8.29--8.43) and average pain (mean 7.13, 95% CI 7.06--7.2) than unlikely NeP respondents who also reported nerve pain for at least 3 of the last 12 months (n=6,155; strongest pain, mean 6.8, 95% CI 6.74--6.86; average pain, mean 5.06, 95% CI 5--5.11). The majority of participants with probable NeP reported pain duration ([Table 4](#t4-jpr-10-2525){ref-type="table"}) of more than 5 years for six of the eleven pain types (arthritis/joint pain, BP, headache/migraine, spinal cord injury, trauma, and other). For three pain types, the majority of participants with probable NeP reported dental/facial pain, shingles, and surgical pain for less than 1 year. Two pain types included a majority of probable NeP respondents who reported experiencing pain for 1--5 years: diabetes-related pain and pelvic pain.

Among respondents reporting nerve pain for at least 3 of the last 12 months, the most commonly reported medication was nonsteroidal anti-inflammatory drugs (48%), followed by weak opioids (32.1%), antiepileptics (11.5%), strong opioids (11.1%), and muscle relaxants (10%). Respondents with probable NeP and self-reported nerve pain for at least 3 of the last 12 months reported taking fewer nonsteroidal anti-inflammatory drugs (41.7%), but more weak opioids (43.1%) and nearly twice the rate of strong opioids (20.9%), muscle relaxants (19.7%), and all adjuvant medications, including antiepileptics (20.2%), antidepressants (12.4%), and *N*-methyl-d-aspartate antagonists (0.9%). "Other" (3%) included acetaminophen and herbal supplements (see [Table 5](#t5-jpr-10-2525){ref-type="table"}).

Discussion
==========

Although some studies have examined the prevalence of broad NeP in Europe,[@b14-jpr-10-2525],[@b26-jpr-10-2525]--[@b30-jpr-10-2525] to our knowledge this is the first study to provide an estimate of the prevalence of probable NeP in the US. A total of 15,751 (63.7%) respondents reported experiencing some pain in the past 12 months, and based on PainDetect scores a weighted estimate of 15.7% had probable NeP. This corresponded to a probable-NeP prevalence of 10% in the US population. The proportion of people reporting pain in this study was higher than other studies, such as the National Health Interview Survey, which found that 56% of adults reported pain,[@b34-jpr-10-2525] and the Gallup--Healthways survey, which found that 47% of adults reported pain.[@b35-jpr-10-2525] These disparities may be related to methodological differences. For example, the prevalence identified in the National Health Interview Survey was likely lower because participants were asked to report pain within the last 3 months, rather than a year, as in our study. Nevertheless, the findings reported in this study are consistent with the range of NeP estimates identified in previous research.[@b14-jpr-10-2525],[@b15-jpr-10-2525],[@b36-jpr-10-2525]--[@b38-jpr-10-2525] For example, the projected rate of probable NeP in the Gallup--Healthways survey of US respondents randomly selected from the general population was 7.4%,[@b35-jpr-10-2525] the prevalence of NeP among adult Minnesotans was 9.8%,[@b15-jpr-10-2525] and a systematic review of studies by van Hecke et al found that NeP prevalence ranged from 6.9% to 10%, but noted a range of 3%--17% in the 21 studies identified.[@b14-jpr-10-2525]

In Europe, the prevalence of NeP ranges from 6.5%[@b39-jpr-10-2525] to 11.8%.[@b40-jpr-10-2525] Torrance et al estimated the prevalence of NeP in the general adult population of the UK at 8%--9% using the Leeds Assessment of Neuropathic Symptoms and Signs.[@b36-jpr-10-2525],[@b38-jpr-10-2525] Bouhassira et al conducted a general-population survey in France using the Douleur Neuropathique 4 (DN4), and found that 6.9% of the population experienced chronic pain with NeP characteristics.[@b37-jpr-10-2525] Similar estimates were reported in Germany (6.5%) using the DN4 and PainDetect.[@b39-jpr-10-2525] A Spanish study of patients treated in the primary care setting reported a slightly higher prevalence of 11.8% for NeP based on clinical assessment.[@b40-jpr-10-2525]

Substantial variation was observed with respect to age and ethnicity. The finding that prevalence of probable NeP was highest among middle-aged Hispanics was unexpected, but there is some precedence for this finding. Prior research has found that severe pain and pain interference is more common among Hispanics and non-Hispanic Blacks than non-Hispanic Whites.[@b41-jpr-10-2525] Further, Hispanics with NeP reported more severe pain than non-Hispanic Whites.[@b42-jpr-10-2525]

With respect to our finding of NeP peaking in middle age, Bouhassira et al also observed the same effect using the DN4 diagnostic tool to assess NeP.[@b37-jpr-10-2525] Other studies in Finland and the Netherlands have found prevalence to be higher among older persons.[@b43-jpr-10-2525],[@b44-jpr-10-2525] The reason for this discrepancy is unclear. A possible explanation is that the US has a higher incidence of type II diabetes than Europe, which could result in increased levels of DPN and thus a younger population with NeP.[@b45-jpr-10-2525] Studies have shown that surgery rates for CLBP, which can result in NeP, are substantially higher in the US than Europe.[@b11-jpr-10-2525] It is also possible that the higher rates of obesity in the US compared to Europe may be causing NeP-related conditions like diabetes and CLBP to occur earlier.[@b46-jpr-10-2525],[@b47-jpr-10-2525]

The results also suggest a significant comorbidity burden among respondents with probable NeP. The greatest differences between those with probable NeP and those unlikely to have it were observed for psychiatric, sleep disorder, and pain-related conditions. This finding is consistent with research conducted in other regions, and highlights the strong interrelationships between pain and mood.[@b48-jpr-10-2525]--[@b50-jpr-10-2525] Additionally, the biggest differences in the pain types reported between respondents with probable NeP and those unlikely to have NeP were for pain types that were predominantly neuropathic in origin (eg, diabetes-related pain, spinal cord-injury pain, and shingles-related pain), indicating some convergence between their responses on the PainDetect and the condition reported.

Nevertheless, there were respondents with probable NeP who reported pain types not typically associated with neuropathic symptoms. This finding is consistent with previous work. A different set of studies was conducted to determine the clinical presentation and burden of illness in six different NeP conditions: HIV NeP,[@b51-jpr-10-2525] posttrauma/postsurgical NeP,[@b52-jpr-10-2525] spinal cord injury with NeP,[@b53-jpr-10-2525] CLBP,[@b42-jpr-10-2525] painful diabetic neuropathy,[@b54-jpr-10-2525] and painful peripheral neuropathy with small-fiber involvement.[@b42-jpr-10-2525] In these studies, physicians and patients were required to answer questions regarding NeP, comorbid medical and psychiatric conditions, and medication to treat NeP. These studies noted an increased incidence of medical and psychiatric conditions that were a function of pain severity. These medical conditions included other NeP conditions, fibromyalgia, restless-leg syndrome, and painful conditions typically thought to be nociceptive, such as rheumatoid arthritis. Therefore, it is not surprising that patients with NeP report an increased incidence of other painful conditions, regardless of their origin.[@b42-jpr-10-2525],[@b51-jpr-10-2525]--[@b55-jpr-10-2525] It is also possible that the 80% specificity[@b22-jpr-10-2525] of PainDetect coded some nociceptive patients as false-positive NeP patients. If our findings are corroborated in future studies, this has important implications for general pain management and treatment.

Limitations
-----------

Although data were obtained from 24,925 respondents, the response rate was very low compared to studies with Internet recruitment (they tend to be 20%--30%), but those studies did not attempt to estimate prevalence.[@b56-jpr-10-2525] However, the low response rate could have resulted in a bias toward respondents who have more painful illnesses than those who chose not to participate, which is evidenced by the finding that the overall rates of pain reported in this study were higher than other studies.[@b34-jpr-10-2525],[@b35-jpr-10-2525] The finding that middle-aged respondents reported higher levels of NeP may also be the result of a self-selection bias; older respondents with NeP could have disproportionately chosen to forgo study participation.

Further, the PainDetect is a screening tool, and the validation studies focused on patients with clear symptomatology. However, it has not been tested in every potential NeP pain (eg, headache). Further, while it might perform well in large-scale epidemiological studies, such as this one, the psychometric properties of the measure have only been examined in studies using selective samples and specific subtypes of NeP. Therefore, it is possible that participants responded in an unexpected manner that may have resulted in an overestimation of prevalence rates.[@b22-jpr-10-2525] Additionally, the diagnosis of NeP cannot replace a thorough clinical assessment. Therefore, it is possible assessments by trained health care providers may yield a different prevalence rate for overall NeP.

Furthermore, all information collected in this study was patient-reported (eg, comorbidities, pain history) and thus subject to recall biases and other self-presentation effects. Additionally, only English-language questionnaires were used, which may have impacted the participation of those who were not fluent speakers of the language.

Conclusion
==========

Among people in the US reporting at least some pain in the last year, 15.7% likely had a syndrome with a neuropathic component. This study suggests prevalence estimates may be higher among some ethnic minorities. Increased attention should be placed on the recognition and treatment of NeP among Hispanics and Blacks, given known health care disparities for pain management[@b57-jpr-10-2525] and evidence suggesting their pain severity and NeP prevalence is higher than Whites. Finally, the management of NeP should be considered in the context of patients' overall pain syndrome and comorbid conditions, as these patients frequently have pain from multiple sources and report higher rates of medical and psychiatric comorbidities.

Supplementary material
======================

###### 

Medications participants reported for nerve pain, categorized by class

  Class                              Medication
  ---------------------------------- ----------------------------
  Antiepileptics                     Carbamazepine
  Lamotrigine                        
  Pregabalin                         
  Topiramate                         
  Zonisamide                         
  Benzodiazepine                     Diazepam
  COX2                               Celecoxib
  GABA                               Baclofen
  Gabapentin                         
  Local anesthetics                  Lidocaine
  Muscle relaxants                   Metaxalone
  Carisoprodol                       
  Cyclobenzaprine                    
  Methocarbamol                      
  Tizanidine                         
  NMDA-receptor antagonists          Ketamine
  NSAIDs                             Diclofenac
  Ibuprofen                          
  Meloxicam                          
  Naproxen                           
  Nabumetone                         
  Other                              Other
  SNRIs                              Duloxetine hydrochloride
  Milnacipran hydrochloride          
  Venlafaxine                        
  Citalopram                         
  Escitalopram                       
  Fluoxetine                         
  Paroxetine                         
  Sertraline                         
  Strong opioids                     Fentanyl
  Hydromorphone hydrochloride        
  Methadone                          
  Morphine                           
  Oxycodone                          
  TCAs                               Amitriptyline HCl
  Desipramine                        
  Imipramine                         
  Tramadol                           Tramadol
  Weak opioids                       Acetaminophen with codeine
  Codeine                            
  Hydrocodone                        
  Hydrocodone bitartrate/ibuprofen   
  Hydrocodone with acetaminophen     
  Hydrocodone with aspirin           
  Tramadol/acetaminophen             

**Abbreviations:** GABA, γ-aminobutyric acid; NMDA, *N*-methyl-d-aspartate; NSAIDs, nonsteroidal anti-inflammatory drugs; SNRIs, serotonin--norepinephrine reuptake inhibitors; SSRIs, selective serotonin-reuptake inhibitors; TCAs, tricyclic antidepressants.
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![Study flowchart.\
**Notes:** \*Weighted data represent the frequency of the sample data after applying sampling weights, which were calculated by incorporating the age, sex, and race/ethnicity of the respondents. The US population is based on the most recent Current Population Survey (June 2015) conducted by the US Census Bureau. \*\*Based on the self-reported question, "Have you experienced any physical pain in the last 12 months?" Patients who responded "Yes" were categorized as having pain for this study. Uppercase N refers to the US population, while lowercase n refers to the sample.\
**Abbreviation:** NeP, neuropathic pain.](jpr-10-2525Fig1){#f1-jpr-10-2525}

![Distribution of PainDetect scores among those with pain (n=15,749).\
**Notes:** Higher scores indicate increased likelihood of neuropathic pain. Respondents who did not self-report experiencing any pain in the past 12 months did not complete the PainDetect (n=9,174). Two respondents with pain in the past 12 months did not complete the PainDetect, and were not included in the PainDetect analyses.](jpr-10-2525Fig2){#f2-jpr-10-2525}

![Heat map of the weighted prevalence of probable neuropathic pain, based on the PainDetect, among those with pain by demographic strata.](jpr-10-2525Fig3){#f3-jpr-10-2525}

![Weighted comorbidity-prevalence estimates among respondents with probable NeP and respondents with pain but unlikely NeP.\
**Notes:** Error bars indicate 95% confidence intervals.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; MS, multiple sclerosis; NeP, neuropathic pain; RLS, restless leg syndrome; RA, rheumatoid arthritis; TIA, transient ischemic attack.](jpr-10-2525Fig4){#f4-jpr-10-2525}

![Weighted pain-type prevalence among respondents with probable NeP and respondents with pain but unlikely NeP.\
**Notes:** Percentage based on those who self-reported having diabetes. Error bars indicate 95% confidence intervals. All pain types were significantly different between groups, with the exception of "Other" (*P*=0.062).\
**Abbreviation:** NeP, neuropathic pain.](jpr-10-2525Fig5){#f5-jpr-10-2525}

###### 

Demographic characteristics of the study sample (n=24,925)

  Demographic characteristic                                             Unweighted   Weighted                               
  ---------------------------------------------------------------------- ------------ ---------- ------------- ------------- ------
  **Sex**                                                                Male         11,925     47.8          116,560,000   48.2
  Female                                                                 13,000       52.2       125,270,000   51.8          
  **Age, years**                                                         18--34       5,400      21.7          72,514,917    30
  35--44                                                                 3,402        13.6       39,698,557    16.4          
  45--54                                                                 4,267        17.1       42,656,469    17.6          
  55--64                                                                 4,473        17.9       40,556,004    16.8          
  65--74                                                                 5,425        21.8       27,363,123    11.3          
  75+                                                                    1,958        7.9        19,040,479    7.9           
  **Race**                                                               White        7,417      29.8          156,760,000   64.8
  Hispanic                                                               5,858        23.5       37,577,888    15.5          
  Black                                                                  6,453        25.9       28,381,681    11.7          
  Other                                                                  5,197        20.9       19,113,108    7.9           
  **Questionnaire modality**                                             Internet     15,088     60.5          139,460,000   57.7
  Telephone                                                              2,907        11.7       36,672,669    15.2          
  Mail                                                                   982          4          14,568,067    6             
  Mall intercept                                                         5,338        21.4       39,342,717    16.3          
  Store-receipt invitation[\*](#tfn1-jpr-10-2525){ref-type="table-fn"}   590          2.4        11,406,801    4.7           
  **Region[\*\*](#tfn2-jpr-10-2525){ref-type="table-fn"}**               East         4,554      18.3          44,367,561    18.4
  Midwest                                                                5,218        20.9       58,095,899    24            
  South                                                                  8,820        35.4       80,982,310    33.5          
  West                                                                   6,286        25.2       57,837,823    23.9          

**Notes:**

Store-receipt invitation refers to a method by which respondents were invited to participate through an Internet link on a store receipt that they received at participating retailers (eg, pharmacies, grocery stores);

State and thus region information was unavailable for 47 respondents.

###### 

Prevalence of NeP based on the PainDetect among all respondents and all respondents with pain by survey modality

  Modality         Among all adults (%)   Among all adults with any pain (%)          
  ---------------- ---------------------- ------------------------------------ ------ --------------
  Internet         10.8                   (10.3--11.3)                         17.2   (16.5--18)
  Mail             8.7                    (7.2--10.8)                          11.3   (9.3--13.8)
  Mall intercept   12.4                   (11.5--13.3)                         15.3   (14.3--16.4)
  Store receipt    8.6                    (6.6--11.2)                          12.2   (9.4--15.7)
  Telephone        4.1                    (3.4--4.8)                           15.4   (13.1--18.1)

**Notes:** Prevalence was estimated using a sample-weighted generalized linear model, controlling for age, sex, and race/ethnicity, and specifying a binomial distribution; models controlled for age, sex, and race/ethnicity, since different modalities were used to attract different demographic strata.

**Abbreviations:** NeP, neuropathic pain; CI, confidence interval.

###### 

Weighted demographic characteristics among respondents with probable NeP and respondents with pain but unlikely NeP

  ------------------------------------------------------------------------------------------------------
  Demographic characteristics   Unlikely NeP\       Probable NeP\                    
                                (PainDetect \<19)   (PainDetect ≥19)                 
  ----------------------------- ------------------- ------------------- ------------ -------------------
  **Sex (%)**                                                                        

  Male                          61,765,757          47.6 (46.4--48.8)   12,013,398   49.6 (46.9--52.3)

  Female                        68,148,016          52.5 (51.3--53.7)   12,193,390   50.4 (47.7--53.1)

  **Age, years (%)**                                                                 

  18--34                        41,137,388          31.7 (30.5--32.9)   8,177,056    33.8 (31.1--36.5)

  35--44                        20,038,205          15.4 (14.6--16.2)   5,277,625    21.8 (19.7--23.9)

  45--54                        22,899,740          17.6 (16.7--18.5)   4,947,003    20.4 (18.3--22.5)

  55--64                        22,374,378          17.2 (16.4--18)     3,481,001    14.4 (12.7--16.1)

  65--74                        15,019,395          11.6 (11--12)       1,524,141    6.3 (5.4--7.2)

  75+                           8,444,667           6.5 (5.7--7.3)      799,963      3.3 (2.5--4.1)

  **Race/ethnicity (%)**                                                             

  White                         84,905,188          65.4 (64.5--66.3)   13,566,229   56 (57.1--54.9)

  Hispanic                      19,994,555          15.4 (14.8--16)     5,442,441    22.5 (21.1--23.9)

  Black                         14,940,179          11.5 (11--12)       3,372,573    13.9 (12.6--15.2)

  Other                         10,073,852          6.5 (6.7--7.9)      1,825,545    7.5 (6.2--8.8)

  **Region (%)**                                                                     

  Northeast                     23,337,766          18 (17.1--18.9)     4,964,442    20.5 (18.4--22.6)

  Midwest                       34,302,737          26.4 (25.3--27.5)   4,943,089    20.4 (18.2--22.6)

  South                         41,166,584          31.7 (30.6--32.8)   8,393,247    34.7 (32.2--37.2)

  West                          30,772,373          23.7 (22.7--24.7)   5,859,445    24.2 (21.9--26.5)
  ------------------------------------------------------------------------------------------------------

**Note:** Column percentages are reported, which provides the percentage of respondents in each row who have probable NeP and unlikely NeP.

**Abbreviations:** NeP, neuropathic pain; CI, confidence interval.

###### 

Respondents' duration of pain by pain type

  Pain type                        Probable NeP (PainDetect ≥19)               
  ----------------------- -------- ------------------------------- ----------- -----------
  Arthritis/joint pain    n        1,880,793                       4,350,453   5,315,768
  \%                      16.29%   37.68%                          46.04%      
  Back pain               n        2,967,346                       6,073,593   7,808,091
  \%                      17.61%   36.05%                          46.34%      
  Dental/facial pain      n        2,404,032                       1,565,175   1,172,127
  \%                      46.76%   30.44%                          22.8%       
  Headache/migraine       n        1,687,695                       2,697,547   4,576,751
  \%                      18.83%   30.1%                           51.07%      
  Diabetes-related pain   n        384,435                         901,935     832,384
  \%                      18.14%   42.57%                          39.29%      
  Pelvic pain             n        1,403,749                       1,873,945   1,566,012
  \%                      28.98%   38.69%                          32.33%      
  Spinal cord injury      n        464,685                         690,022     978,399
  \%                      21.78%   32.35%                          45.87%      
  Shingles                n        432,924                         405,714     240,809
  \%                      40.11%   37.59%                          22.31%      
  Surgical                n        1,303,247                       927,156     762,799
  \%                      43.54%   30.98%                          25.48%      
  Trauma pain             n        918,365                         922,028     1,890,530
  \%                      24.61%   24.71%                          50.67%      
  Other                   n        483,577                         852,812     1,497,146
  \%                      17.07%   30.1%                           52.84%      

**Abbreviation:** NeP, neuropathic pain.

###### 

Current NeP-medication use by respondents who self-reported experiencing nerve pain for at least 3 months

  NeP-medication             All respondents self-reporting nerve pain   Probable NeP respondents self-reporting nerve pain                                   
  -------------------------- ------------------------------------------- ---------------------------------------------------- ------------ ----------- ------ ------------
  NSAID                      38,342,532                                  48                                                   46.5--49.5   8,738,205   41.7   38.9--44.5
  Weak opioid                25,634,060                                  32.1                                                 30.7--33.4   9,035,284   43.1   40.3--46
  Antiepileptic              9,173,723                                   11.5                                                 10.5--12.4   4,238,701   20.2   17.9--22.5
  Strong opioid              8,890,192                                   11.1                                                 10.2--12.1   4,369,720   20.9   18.5--23.2
  Muscle relaxant            7,955,673                                   10                                                   9.1--10.9    4,141,427   19.7   17.4--22.1
  Tramadol                   5,356,325                                   6.7                                                  6--7.4       2,440,161   11.6   9.8--13.5
  SSRI                       5,062,934                                   6.3                                                  5.6--7.1     2,603,209   12.4   10.4--14.4
  TCA                        2,640,531                                   3.3                                                  2.8--3.8     1,594,214   7.6    6.1--9.2
  SNRI                       2,725,170                                   3.4                                                  2.9--4       1,584,318   7.6    6--9.1
  COX2 inhibitor             2,293,024                                   2.9                                                  2.4--3.3     1,012,713   4.8    3.6--6
  Benzodiazepine             2,216,143                                   2.8                                                  2.3--3.3     1,284,562   6.1    4.7--7.6
  Local anesthetic           1,303,814                                   1.6                                                  1.2--2       560,863     2.7    1.8--3.6
  NMDA-receptor antagonist   330,978                                     0.4                                                  0.2--0.6     185,745     0.9    0.3--1.4
  Other                      3,926,884                                   5                                                    4.3--5.6     631,249     3      2--4

**Abbreviations:** NeP, neuropathic pain; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug; SSRI, selective serotonin-reuptake inhibitor; TCA, tricyclic antidepressant; SNRI, serotonin--norepinephrine reuptake inhibitor; NMDA, *N*-methyl-d-aspartate.
